Treatment Strategies in Endogenous Fungal Endophthalmitis

Management of endogenous fungal endophthalmitis is complex, with wide variation in treatment strategies. Systemic markers of disease appear to influence the choice of initial therapy more than ocular findings. Although no definitive evidence favors IV over oral systemic therapy, a comprehensive, multidisciplinary approach that considers ocular involvement is essential to optimize patient outcomes in EFE.

By
Arthi Venkat, MD, MS
Eleanor M. Burton, MD
January 1, 2026
7 min

Retinal Physician

Overview

This report summarizes findings from a multicenter study on treatment strategies for endogenous fungal endophthalmitis (EFE), highlighting significant variations in therapy selection and outcomes based on clinical characteristics and geographic regions. The study emphasizes the importance of systemic and intravitreal antifungal therapies in managing this vision-threatening condition.

Background

Endogenous fungal endophthalmitis accounts for 5% to 10% of all endophthalmitis cases, often resulting from hematogenous spread of infection. It poses a significant risk to vision, necessitating effective treatment strategies that combine systemic and intraocular therapies. Current guidelines are limited, and there is a need for improved understanding of optimal management approaches.

Data Highlights

{'format': 'Ensure the table is visually clear and accessible.'}

Key Findings

72% of eyes received combination systemic and intravitreal antifungals.
Voriconazole and fluconazole were the most frequently used initial systemic agents.
Patients with positive systemic cultures were more likely to receive IV antifungals.
Only 30% of eyes underwent surgical intervention, with oral therapy associated with higher surgery rates.
Amphotericin B was the most frequently administered intravitreal agent.

Clinical Implications

Clinicians should consider the use of both systemic and intravitreal antifungal therapies in managing EFE, particularly in cases with significant ocular involvement. The choice between oral and IV antifungal agents may depend on culture results and clinical presentation, emphasizing the need for tailored treatment strategies.

Conclusion

The findings from this multicenter study underscore the complexity of managing endogenous fungal endophthalmitis and highlight the necessity for further research to establish clearer guidelines and optimize treatment outcomes.